Northeast Financial Consultants’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Northeast Financial Consultants’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,068	Closed	-$235K	–	338
2022 Q4	$235K	Buy	+2,068	New	+$172K	0.02%	274
2022 Q2	–	Sell	-2,102	Closed	-$221K	–	398
2022 Q1	$221K	Hold	2,102	–	–	0.01%	357
2021 Q4	$227K	Hold	2,102	–	–	0.01%	323
2021 Q3	$230K	Buy	+2,102	New	+$218K	0.02%	317

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northeast Financial Consultants's HZNP Position: Q1 2023 in Review

Northeast Financial Consultants sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 2,068 shares — an estimated $235K sold.

Northeast Financial Consultants first reported a position in HZNP in Q3 2021 and held it in 4 quarters. The position peaked at $235K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Northeast Financial Consultants reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Northeast Financial Consultants sold 2,068 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $235K.
Northeast Financial Consultants first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 4 quarters.
Northeast Financial Consultants's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $235K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Northeast Financial Consultants's 13F filing for Q1 2023, filed 15 May 2023.